9 Einträge gefunden

1. Primary tumor dependent inhibition of tumor growth, Angio-Genesis, and perfusion of secondary breast cancer in bone.

   1. Schäfer, Christian
   2. Schröder, Malte
   3. Fuhrhop, Ina
   4. Viezens, Lennart
   5. Wellbrock, Jasmin
   6. Fiedler, Walter
   7. Rüther, Wolfgang

   2011 - Forschungsinformationssystem des UKE
2. Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.

   1. Schultze, Alexander
   2. Fiedler, Walter

   2011 - Forschungsinformationssystem des UKE
3. Clinical experience with antiangiogenic therapy in leukemia.

   1. Wellbrock, Jasmin
   2. Fiedler, Walter

   2011 - Forschungsinformationssystem des UKE
4. Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.

   1. Desar, [Unbekannt]
   2. Ingrid, M E
   3. Herpen, van
   4. Carla, M L
   5. Asten, van
   6. Jack, J A
   7. Fiedler, Walter

   2011 - Forschungsinformationssystem des UKE
5. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.

   1. Damm, Frederik
   2. Heuser, Michael
   3. Morgan, Michael
   4. Wagner, Katharina
   5. Görlich, Kerstin
   6. Grosshennig, Anika
   7. Hamwi, Iyas

   2011 - Forschungsinformationssystem des UKE
6. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).

   1. Grünwald, Viktor
   2. Desar, Ingrid M E
   3. Haanen, John
   4. Fiedler, Walter
   5. Mouritzen, Ulrik
   6. Olsen, M W Brændholt
   7. Herpen, van

   2011 - Forschungsinformationssystem des UKE
7. Phase I trial of SU14813 in patients with advanced solid malignancies.

   1. Fiedler, Walter
   2. Giaccone, G
   3. Lasch, P
   4. van der Horst, I
   5. Brega, N
   6. Courtney, R
   7. Abbattista, A

   2011 - Forschungsinformationssystem des UKE
8. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.

   1. Schimmer, Aaron D
   2. Herr, Wolfgang
   3. Hänel, Mathias
   4. Borthakur, Gautham
   5. Frankel, Arthur
   6. Horst, Heinz-August
   7. Martin, Sonja

   2011 - Forschungsinformationssystem des UKE
9. Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.

   1. Kobold, Sebastian
   2. Isernhagen, Julie
   3. Hübel, K
   4. Kilic, Nerbil
   5. Bogner, C
   6. Frickhofen, N
   7. Bokemeyer, Carsten

   2011 - Forschungsinformationssystem des UKE